To receive email alerts directly from AxoGen, please click here www.axogeninc.com/emailalerts.html.
AxoGen, Inc. (OTCBB: AXGN) today announced that it will be presenting at the JMP Securities Healthcare Conference at The Peninsula in New York City, NY. Karen Zaderej, AxoGen’s Chief Executive Officer will give a Company presentation on Thursday, July 12, 2012, at 10:30 AM Eastern Time. A live audio broadcast of AxoGen’s conference presentation will be available through the Company’s website, www.AxoGenInc.com. Following the live presentation, a replay can be heard on this same website. About AxoGen, Inc. AxoGen (OTCBB: AXGN) is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent- pending technologies, which are used in its portfolio of products. This portfolio includes Avance® Nerve Graft, the only commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed) of 5mm to 70mm in length. AxoGen’s portfolio also includes AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves gaps up to 5mm in length, and AxoGuard® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue. AxoGen brings the science of nerve repair to life with thousands of surgical implants of AxoGen products and technology performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.